Plus Therapeutics to Provide Update on ReSPECT Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (GlobeNewswire) - Nov 2, 2022 - "Plus Therapeutics...announced it will present data from two ongoing clinical trials evaluating the Company's lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, in recurrent glioblastoma, leptomeningeal metastases, as well as clinical trial plans for pediatric brain cancer at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) being held November 16-20, 2022....Recurrent glioblastoma and leptomeningeal metastases data have been selected for oral presentations. Pediatric brain cancer plans will be shared via poster session."
New P2b trial • P1 data • P1/2 data • Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|